Inflammatory Diseases
The focus is on several different inflammatory diseases, including rheumatic diseases (rheumatoid arthritis, SLE, myositis), neuroimmune diseases (such as MS), inflammatory skin diseases, (in particular psoriasis) and several others. The common strategy is to identify environmental as well as genetic risk factors, and how genes and environment in concert trigger immune reactions that may cause the different diseases. This knowledge is used as a basis for development of prevention and new therapies.
Groups
-
We investigate the mechanisms whereby the body's immune system attacks itself, 'autoimmune diseases,' including Multiple Sclerosis (an inflammatory condition of the nervous system) and type I diabetes (an inflammatory condition affecting the pancreas) and we develop new therapies for these diseases.
-
Psoriasis is a chronic immune system-related disease that causes inflammation and damage to involved tissues, primarily the skin. Our research groups focus on the biology, genetics and epidemiology of this disease.
-
Characterizations of microsomal prostaglandin E synthase 1 and novel pathogenic mechanisms in rheumatic diseases
-
We study blood cancer in the Swedish population - familial risk factors, precancerous conditions, prognosis and treatment related complications. Findings are related to biological characteristics of the tumor forming a base for new diagnostic and treatment principles
-
-
Autoimmune disorders are a major cause of disease and disability, affecting more than 5% of the population. We study the rheumatic autoimmune condition Sjögren’s syndrome, and the autoantibody mediated congenital heart block that may develop in the fetus of pregnant women with Sjögren’s syndrome.
-
-
Our research is focused on the molecular mechanisms that cause impaired muscle performance if you develop myositis and on risk factors for development of rheumatic muscle inflammation, myositis
-
We study the neurodegenerative disease Multiple Sclerosis which has a prevalence that ranges between 2-150 per 100,000, identifying genes and defining immunological mechanisms that predispose to the disease, in both clinical and preclinical settings.
-